Madrigal Pharmaceuticals (NASDAQ:MDGL) reported better-than-expected earnings for the fourth quarter of 2024, with an earnings per share (EPS) of -2.71 USD, surpassing the forecast of -4.48 USD.

Jude K. Osasere Osayawe selected as 2025 American Chemical Society Pharma Scholar The BYU Chemistry and Biochemistry wish Jude K. Osasere Osayawe the best in his continuing research. (Jude K.

JM Financial has a buy call on Sun Pharmaceutical Industries with a target price of Rs 2115. The current market price of Sun Pharmaceutical Industries is Rs 1655.2. The time period given by the ...

Private equity-backed US pharmaceutical giant Cosette has made a $672 million cash takeover bid for women’s health and dermatology group Mayne Pharmaceuticals. The company, which last week ...

OAKVILLE, Ontario — Harvest Portfolios Group Inc. (“Harvest”) declares the monthly cash distribution payable for Big Pharma Split Corp. of $0.1031 for each class A share (PRM:TSX) for the month ending ...

President Irfaan Ali yesterday oversaw the execution of two Memoranda of Understanding (MoUs) – including one on pharmaceutical services – on the sidelines of the 48th Regular Meeting of ...

One Indian pharmaceutical company dey manufacture unlicensed, highly addictive opioids and dey export dem illegally to West Africa wia dem dey drive a major public health crisis for countries ...

(Alliance News) - Hookipa Pharma Inc on Thursday said it is not going ahead with a bid for Poolbeg Pharma PLC. In a brief statement regarding a possible combination between the two firms ...

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complet ...

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $90.00. The company’s shares closed yesterday at ...

Driving innovation in obesity with differentiated mid- to late-stage pipeline “2024 was a transformational year for Zealand Pharma with positive data across our mid- to late-stage obesity pipeline and ...

Driving innovation in obesity with differentiated mid- to late-stage pipeline “2024 was a transformational year for Zealand Pharma with positive data across our mid- to late-stage obesity ...